

In the Claims

Claims 1-16 (Cancelled)

Claim 17 (Currently amended): A method of ~~suppressing the growth of cancerous cells for inhibiting the growth of a tumor in a mammal, comprising introducing a nucleic acid construct comprising an effective amount of a nucleic acid sequence encoding wild-type RhoB protein into the cancerous cells associated with the tumor, wherein the nucleic acid sequence is expressed and an effective amount of RhoB protein is produced in the cancerous cells.~~

Claim 18 (Currently amended): The method of claim 17, wherein the nucleic acid ~~construct sequence~~ is introduced into the ~~cancerous~~ cells within a viral vector.

Claims 19-22 (Cancelled)

Claim 23 (Currently amended): The method of ~~claim 20~~ claim 17, wherein the mammal is human.

Claim 24 (Currently amended): The method of ~~claim 20~~ claim 17, wherein the method further comprises administering at least one additional therapy to the mammal, wherein the therapy is selected from the group consisting of chemotherapy, radiation therapy, and therapy that selectively inhibits Ras oncogenic signaling.

Claim 25 (Currently amended): The method of claim 17, wherein the ~~cancerous~~ cells are cells of a solid tumor.

Claim 26 (Currently amended): The method of claim 17, wherein the ~~cancerous~~ cells are cancer cells of a type selected from the group consisting of ~~lung cancer cells, pancreatic cancer cells,~~

~~prostate cancer cells, and melanoma cancer cells pancreatic cancer, prostate cancer, breast cancer, colon cancer, rectal cancer, lung cancer, and melanoma.~~

Claims 27-34 (Canceled)

Claim 35 (New): The method of claim 17, wherein the cells are cancer cells of a type selected from the group consisting of brain cancer, oral cancer, laryngeal cancer, thyroid cancer, and esophageal cancer.

Claim 36 (New): The method of claim 17, wherein the cells are lung cancer cells.

Claim 37 (New): The method of claim 17, wherein the cells are liver cancer cells.

Claim 38 (New): The method of claim 17, wherein the cells are melanoma cells.

Claim 39 (New): The method of claim 17, wherein the nucleic acid sequence is associated with a pharmaceutically acceptable carrier.